https://charts.traderzeitung.de/phases/US15117N7012 string(1431) "{"isin":"US15117N7012","name":"Imunon Inc","stock_id_xnas":132475559,"stock_id_xnys":132475560,"generated_at":"2026-09-24 01:33:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.44,"close_at":"2026-09-21 20:16:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":1.46,"close_at":"2026-09-21 23:12:00","complete":true,"perf_pct":1.3889}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.52,"close_at":"2026-09-22 21:55:00","complete":true,"perf_pct":4.1096},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.64,"close_at":"2026-09-23 10:23:00","complete":true,"perf_pct":7.8947},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.45,"close_at":"2026-09-23 21:49:00","complete":true,"perf_pct":-11.5854},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Imunon Aktie News & Nachrichten

[WKN: A41CNR | Symbol: IMNN]

Realtimekurs

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Imunon gefunden werden.

Imunon Nachrichtenticker öffnen

MT Newswires 30.07.2026 16:12 Uhr

Imunon meldet über den Erwartungen liegende Rekrutierung in Phase-3-Studie mit IMNN-001 zur Behandlung von Eierstockkrebs

10:11 AM EDT, 30.07.2026 (MT Newswires) -- Imunon (IMNN) teilte am Donnerstag mit, dass bei der Phase-3-Studie Ovation 3 mit IMNN-001 bei Patientinnen

MT Newswires 21.07.2026 15:37 Uhr

Imunon meldet, dass vorläufige Ergebnisse der Studie zum Eierstockkrebs-Medikament ein stärkeres Antitumor-Ansprechen zeigen

09:36 AM EDT, 21.07.2026 (MT Newswires) -- Imunon (IMNN) teilte am Dienstag mit, dass vorläufige Daten aus der laufenden klinischen Phase-2-Studie mit

MT Newswires 23.06.2026 14:49 Uhr

Imunons Phase-3-Eierstockkrebsstudie darf fortgesetzt werden

08:48 AM EDT, 06/23/2026 (MT Newswires) -- Imunon (IMNN) teilte am Dienstag mit, dass ein unabhängiges Datenüberwachungskomitee die Fortsetzung der Ph